Corpus Intelligence IC Memo — LOWER BUCKS HOSPITAL 2026-04-26 09:36 UTC
IC Memo — LOWER BUCKS HOSPITAL
Investment Committee Memorandum | PA | 105 beds | Grade D | EBITDA uplift $4.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

LOWER BUCKS HOSPITAL

CCN 390070 | BUCKS, PA | 105 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

LOWER BUCKS HOSPITAL is a 105-bed under-performing / distressed in BUCKS, PA with $63.6M in net patient revenue and a -14.7% operating margin. The hospital serves a payer mix of 22.4% Medicare, 2.5% Medicaid, and 75.1% commercial.

Thesis: Undervalued. Our ML models identify $4.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -14.7% to -7.4% (+736bps).

Net Revenue HCRIS$63.6M
Current EBITDA COMPUTED$-9.4M
Operating Margin COMPUTED-14.7%
Occupancy HCRIS24.3%
Revenue / Bed COMPUTED$606K
Net-to-Gross HCRIS18.6%
Distress Probability ML53.1%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
101
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -14.7% places it below the state median. Among 101 size-comparable peers (52-210 beds), the median margin is -4.1%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (52-210), prioritizing same-state peers. 101 hospitals in the comp set.

HospitalStateBedsRevenueMargin
LOWER BUCKS HOSPITAL (Target)PA105$63.6M-14.7%
ST LUKE HOSPITAL ANDERSON CAMPPA193$433.0M20.6%
THE GETTYSBURG HOSPITALPA76$341.8M18.4%
ST. JOSEPH MEDICAL CENTERPA132$334.8M13.2%
EPHRATA COMMUNITY HOSPITALPA115$291.8M3.8%
EINSTEIN MEDICAL CENTER MONTGOPA175$276.3M6.9%
THE GOOD SAMARITAN HOSPITALPA145$269.5M-5.0%
WILKES-BARRE GENERAL HOSPITALPA188$262.1M-13.0%
UPMC ST MARGARETPA185$248.5M-21.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.3M+210bp18mo
Cost to Collect4.5%2.5%$1.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$775K+122bp9mo
Clean Claim Rate88.0%96.0%$41K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.3M
Cost to Collect
$1.3M
Denial Rate Reduction
$1.3M
A/R Days Reduction
$775K
Clean Claim Rate
$41K
Total EBITDA Uplift$4.7M
Current EBITDA$-9.4M
+ RCM Uplift+$4.7M
Pro Forma EBITDA$-4.7M
Current Margin-14.7%
Pro Forma Margin-7.4%
WC Released (1x)$2.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-14.4M$-15.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-14.4M$-21.2M0.00x-100.0%
Bull Case9.0x11.0x$-13.0M$-10.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-13.0M$-15.2M0.00x-100.0%
Bear Case11.0x10.0x$-15.9M$-33.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-15.9M$-42.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 24.3%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 53.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 101 hospitals with 52-210 beds
  • Same-state prioritization (n=102)
  • Comp margins: P25=-19.1% / P50=-4.1% / P75=7.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.